Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Combined androgen blockade

E D Crawford1

  • 1Division of Urology, University of Colorado Health Sciences Center, Denver 80262, USA.

European Urology
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Combined androgen blockade (CAB) improves survival for advanced prostate cancer patients. Further studies are exploring which patient groups benefit most from this treatment, using prostate-specific antigen as a marker.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrating central nervous system metagenomics and host response for diagnosis of tuberculosis meningitis and its mimics.

Nature communications·2022
Same author

Corroborating evidence refutes batch effect as explanation for fetal bacteria.

Microbiome·2021
Same author

Viable bacterial colonization is highly limited in the human intestine in utero.

Nature medicine·2020
Same author

Acute West Nile Virus Meningoencephalitis Diagnosed Via Metagenomic Deep Sequencing of Cerebrospinal Fluid in a Renal Transplant Patient.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same author

Depletion of Abundant Sequences by Hybridization (DASH): using Cas9 to remove unwanted high-abundance species in sequencing libraries and molecular counting applications.

Genome biology·2016
Same author

Genetic variation in the vitamin d pathway in relation to risk of prostate cancer--results from the breast and prostate cancer cohort consortium.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2013
Same journal

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same journal

Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer: Recurrent High-risk NMIBC: One Bladder, Choose Wisely.

European urology·2026
Same journal

Re: Dries Develtere, Riccardo Bertolo. Cumulative Genitourinary Toxicity After Prostate Radiotherapy: High-Level Long-Term Randomized Evidence. J Clin Oncol. Online ahead of print. http://dx.doi.org/10.1200/JCO-26-00436.

European urology·2026
Same journal

In Memory of Paul Mitrofanoff (1934-2025).

European urology·2026
Same journal

Re: McKay RR, Pal S, Xie W, et al. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert Consensus on the Management of Renal Cell and Urinary Tract Cancers. CA Cancer J Clin 2026;76:e70052.

European urology·2026
Same journal

Re: Ultra-hypofractionated Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: 5-year Outcomes from a Pooled Analysis of the FASTRACK Trials.

European urology·2026
See all related articles

Area of Science:

  • Oncology
  • Urology

Background:

  • Combined androgen blockade (CAB) involves adding an antiandrogen to castration for advanced prostate cancer.
  • CAB is an established treatment option for advanced prostate cancer, showing promise in improving patient outcomes.

Purpose of the Study:

  • To evaluate the efficacy of CAB in advanced prostate cancer.
  • To identify patient subgroups that benefit most from CAB.
  • To assess prostate-specific antigen (PSA) as a surrogate marker for response and progression in CAB therapy.

Main Methods:

  • A large intergroup study involving over 1,300 men with advanced prostate cancer.
  • Comparison of orchidectomy with flutamide versus orchidectomy with placebo.
  • Analysis of prostate-specific antigen levels as a marker for treatment response.

Related Experiment Videos

Main Results:

  • CAB, specifically with leuprolide and flutamide, demonstrated improved progression-free and overall survival compared to leuprolide alone.
  • These benefits were particularly noted in patients with minimal metastatic disease.
  • The study provided crucial data on PSA as a reliable surrogate marker for treatment efficacy and disease progression.

Conclusions:

  • Combined androgen blockade is a valuable treatment strategy for advanced prostate cancer, enhancing survival and quality of life.
  • Ongoing research aims to refine CAB application by identifying specific patient subgroups for maximal benefit.
  • The use of PSA monitoring is validated as an important tool in managing prostate cancer patients undergoing CAB.